A clinical trial uses PEGPH20, a synthetic form of a human enzyme, to make treatment more effective in pancreatic cancer patients with high tumor pressure.
A clinical trial tests a drug that turns off chemical signals in the body that promote the growth of tumors and the spread of pancreatic cancer.
Drs. Allyson Ocean and David Tuveson explain why pancreatic cancer patients should participate in clinical trials at the time of diagnosis.
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?
A chemoradiation clinical trial tests standard chemotherapy plus an anti-malaria drug and compares two types of radiation treatments, to slow tumor growth.
Researchers are testing a new combination of chemotherapies and radiation to shrink pancreatic cancer tumors and make surgical removal possible.
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
A clinical trial tests the effectiveness of an approved colon cancer drug against advanced pancreatic neuroendocrine cancer.
A clinical trial tests whether a malaria drug can make standard chemotherapy for advanced pancreatic cancer more effective.
A clinical trial compares two chemotherapy regimens to see which one is more effective at knocking out remaining cancer cells.
For patients with stable metastatic pancreatic cancer, a clinical trial compares standard chemotherapy with immunotherapy.
A clinical trial seeks pancreatic cancer patients with the MSI (microsatellite instability) genetic signature, to test an immunotherapy drug.
A clinical trial uses a new immunotherapy drug in combination with standard chemotherapy drugs in metronomic therapy to treat metastatic pancreatic cancer.